SCHEMBL9890702

SCHEMBL9890702

COC(=O)C(O)c1ccccc1-c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
NOTUM Q6P988 2/20 0.46
SCN9A Q15858 1/20 0.42
KLRK1 P26718 1/20 0.42
MICA Q29983 1/20 0.42
DHODH Q02127 1/20 0.41
AKR1C3 P42330 2/20 0.40
AKR1C2 P52895 2/20 0.40
SLC22A12 Q96S37 1/20 0.40
RORB Q92753 1/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
KDR P35968 2/20 0.40
RAB9A P51151 1/20 0.40
AR P10275 2/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
PDK1 Q15118 1/20 0.40
GRM4 Q14833 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890806 0.84 RORB (0.42) KDM4ENOTUMSCN9AKLRK1MICA
SCHEMBL9890705 0.79 AKR1C3 (0.47) KDM4EAKR1C3AKR1C2RORB
SCHEMBL9890688 0.77 HSP90AA1 (0.46) RORBRAB9A
SCHEMBL9890691 0.77 KCNA5 (0.46) RORB
SCHEMBL9890687 0.75 SLC6A4 (0.55) KDM4ELMNAGAAMAPT
SCHEMBL9890693 0.75 NR3C2 (0.44) LMNA
SCHEMBL9890704 0.75 ALDH1A1 (0.43) GAAKDRRAB9A
SCHEMBL9890698 0.75 CASP1 (0.44) KDM4EAKR1C3AKR1C2LMNAGAA
SCHEMBL9890703 0.75 DHODH (0.42) DHODH
SCHEMBL9890686 0.75 TUBB4A (0.44) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KDM4E 829/4885NOTUM 1039/4885SCN9A 109/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KDM4E 829/4885NOTUM 1039/4885SCN9A 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.